Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.70) by 5.71 percent. This is a 65.8 percent increase over losses of $(1.93) per share from the same period last year.
Truist Securities Maintains Buy on Primerica, Raises Price Target to $160
Truist Securities analyst Mark Hughes maintains Primerica (NYSE:PRI) with a Buy and raises the price target from $150 to $160.
